China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Abstract Background On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more li...

Full description

Bibliographic Details
Main Authors: Ming Zhou, Xiaoyuan Chen, Hong Zhang, Lin Xia, Xin Tong, Limin Zou, Ruimin Hao, Jianhong Pan, Xiao Zhao, Dongmei Chen, Yuanyuan Song, Yueli Qi, Ling Tang, Zhifang Liu, Rong Gao, Yuankai Shi, Zhimin Yang
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:Cancer Communications
Subjects:
Advanced non-small cell lung cancer
Anlotinib
Anti-angiogenesis
Epidermal growth factor receptor
Activating anaplastic lymphoma kinase
Adverse drug reaction
Online Access:http://link.springer.com/article/10.1186/s40880-019-0383-7

Internet

http://link.springer.com/article/10.1186/s40880-019-0383-7

Similar Items